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Objectives: Stereotactic body radiation therapy (SBRT) takes advantage of the prostate’s
low α/β ratio to deliver a large radiation dose in few fractions. Initial studies on small groups
of low-risk patients support SBRT’s potential for clinical efficacy while limiting treatment-
related morbidity and maintained quality of life. This prospective study expands upon prior
studies to further evaluate SBRT efficacy for a large patient population with organ confined,
low- and intermediate-risk prostate cancer patients.
Methods: Four hundred seventy-seven patients with prostate cancer received CyberKnife
SBRT. The median age was 68.6 years and the median PSA was 5.3 ng/mL. Three hun-
dred twenty-four patients were low-risk (PSA <10 ng/mL and Gleason <7), 153 were
intermediate-risk (PSA 10–20 ng/mL or Gleason=7). Androgen deprivation therapy was
administered to 51 patients for up to 6 months. One hundred fifty-four patients received
35 Gy delivered in five daily fractions; the remaining patients received a total dose of
36.25 Gy in five daily fractions. Biochemical failure was assessed using the phoenix
criterion.
Results: Median follow-up was 72 months.The median PSA at 7 years was 0.11 ng/mL. Bio-
chemical failures occurred for 11 low-risk patients (2 locally), 14 intermediate-risk patients (3
locally).The actuarial 7-year freedom from biochemical failure was 95.6 and 89.6% for low-
and intermediate-risk groups, respectively (p<0.012). Among patients with intermediate-
risk disease, those considered to have low intermediate-risk (Gleason 6 with PSA >10, or
Gleason 3+4 with PSA <10; n=106) had a significantly higher bDFS than patients with
high intermediate-risk (Gleason 3+4 with PSA 10–20 or Gleason 4+3; n=47), with bDFS
of 93.5 vs. 79.3%, respectively. For the low-risk and low intermediate-risk groups, there
was no difference in median PSA nadir or biochemical disease control between doses of
35 and 36.25 Gy.
Conclusion: CyberKnife SBRT produces excellent biochemical control rates. Median PSA
levels compare favorably with other radiation modalities and strongly suggest durability of
response. These results also strongly suggest that 35 Gy is as effective as 36.25 Gy for
low- and intermediate-risk patients.
Keywords: prostate cancer, stereotactic radiotherapy
INTRODUCTION
Since the first report of a highly hypofractionated regimen for
prostate cancer was published over 20 years ago (1), many addi-
tional reports documenting the use of five-fraction dose schemes
utilizing special image-guided technology, termed stereotactic
body radiotherapy (SBRT), have appeared (2–6), with excellent
outcomes. Biochemical disease-free survival (bDFS) for low-risk
prostate cancer is greater than 90% for SBRT. These results are
consistent with radiobiological data suggesting that prostate can-
cer is especially responsive to changes in dose per fraction, with
α/β ratio for prostate cancer is approximately 1.5 (7, 8). SBRT
has potential to increase the number of patients worldwide who
can access treatment, due to the marked decrease in the number
of fractions required. Cost and patient convenience can also be
favorably impacted (9).
Up until recently, excellent early results have been met with
some skepticism over the durability of these early results. This has
led to reluctance on the part of the radiotherapy community to
embrace this treatment method, in spite of recent support of this
treatment by ASTRO and NCCN (10, 11). To address this concern,
we present the biochemical outcomes of a large cohort of low- and
intermediate-risk patients treated with Cyberknife SBRT with as
long as 8-year follow-up. Toxicity and quality of life (QOL) data
on these patients will be presented in greater detail separately.
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MATERIALS AND METHODS
PATIENT SELECTION
The study cohort was composed of 477 men with biopsy-proven,
newly diagnosed non-metastatic prostate cancer, treated between
early 2006 and January 2010 at Winthrop University Hospital. Data
were analyzed for all clinically localized, low- or intermediate-
risk prostate cancer patients, treated with CyberKnife SBRT. The
treatment protocol was IRB-approved and the first 15 patients
were treated in a prospective fashion to assess the feasibility of the
approach in our hands. Subsequent patients were treated accord-
ing to this approved protocol, but not as part of a prospective
study. All patients provided informed consent for their outcomes
to be incorporated in this retrospective study.
For the purposes of this analysis, we include only the low- and
intermediate-risk patients, following standard D’Amico risk strat-
ification (low-risk: PSA <10 and Gleason sum of 6 and clinical
stage T1c–T2a, intermediate-risk: PSA 10–20 or Gleason sum of 7
or clinical stage T2b).
TREATMENT
Fiducial-based image-guided SBRT was delivered using the
CyberKnife system (Accuray Inc., Sunnyvale, CA, USA). The treat-
ment specifics of Cyberknife have been published previously (12).
General techniques are briefly outlined here. Four gold fiducials
were placed in the prostate trans-perineally with ultrasound guid-
ance. This was followed by a non-contrast CT scan in the supine
position and in an alpha cradle. Except for those patients that
could not undergo an MRI scan, MRI images were obtained and
fused into the CT images to better visualize the inferior portion
of the prostate. No catheter was used. Anatomical contours of the
prostate, seminal vesicles, rectum, bladder, penile bulb, femoral
heads, and testes were generated. With homogeneous planning,
dose was prescribed to the planning target volume (PTV) that con-
sisted of a volumetric expansion of the prostate by 5 mm, reduced
to 3 mm in the posterior direction. During a typical 45-min treat-
ment, fiducial seeds were tracked and adjustments to position
were made at 30–60 s intervals. For each morning prior to SBRT,
patients underwent a bowel prep including Dulcolax® (Boehringer
Ingelheim, Germany) and a Fleet® Enema (C.B. Fleet Company,
Inc., Lynchburg, VA, USA). In addition, at least 15–20 min before
treatment, all patients received 1500 mg of amifostine (MedIm-
mune, LLC Gaithersburg, MD, USA), mixed in saline and instilled
into the rectum (13). The dose of radiotherapy consisted of either
35 or 36.25 Gy over five fractions, given daily for all patients.
The initial 50 patients received 35 Gy. At that time, Stanford pub-
lished on the feasibility of 36.25 Gy and we increased the dose for
the next 30 months. After observing increased toxicity, we pulled
the dose back to 35 Gy for the low-risk and low intermediate-
risk (Gleason 6 with PSA >10, or Gleason 3+ 4 with PSA <10)
patients.
For the homogenous planning, used in all patients, dose was
normalized to the 83–87% isodose line in order for the prescrip-
tion dose to cover at least 95% of the PTV. Generally speaking,
dose volume histogram (DVH) goals for the rectum were such
that the V50% <50% (i.e., the volume receiving 50% of the pre-
scribed dose was<50%), V80%<20%, V90%<10%, and V100%
<5%. The bladder DVH goals were V50% <40% and V100%
<10%. For the bladder and the rectum, a typical D50 was 40–
45% of the maximum dose. The femoral head DVH goal was
V40% <5%. Urethra was not contoured as there was no urethral
constraint.
FOLLOW UP
The median follow up for the entire cohort was 72 months (0–
96 months). In general, PSA values were obtained at baseline,
and prospectively at 3 months post-treatment intervals during
the first 2 years and at 6 months intervals thereafter. The PSA
relapse definition used was the currently adopted standard of
care Phoenix definition (i.e., nadir+ 2) (14). bDFS was calculated
with the Kaplan–Meier method and differences between groups
determined by the log-rank test. A benign PSA bounce was called
when PSA rose by>0.2 ng/mL above the post-treatment nadir and
subsequently returned to nadir levels or below.
TOXICITY
Acute and late genitourinary (GU) and gastrointestinal (GI)
toxicity was scored according to the criteria set forth by RTOG (15).
STATISTICAL ANALYSIS
The primary endpoint of the study was interval to bDFS. Kaplan–
Meier survival method was used to estimate bDFS and log-rank
p-values were used to compare the distributions. Cox regression
analysis was used to significant risk factors. For Cox regression
analysis, the assumption of the proportional hazards model was
tested to ensure these assumptions were not violated. Two sided
p< 0.05 was considered to be statistically significant. JMP Pro 10
(SAS Institute, Cary, NC, USA) was used for statistical analyses. For
the multivariate analysis, categorical variables included were age
(below vs. above median age of 68.6 years), hormones (no hor-
mones vs. hormones), PSA (below vs. above 10 ng/mL), T-stage
(T1 vs. T2), and Gleason score (Gleason 6, 3+ 4 vs. Gleason 4+ 3).
RESULTS
PATIENT CHARACTERISTICS
Using this stratification, 324 patients were low-risk and 153
were intermediate-risk. Patient characteristics are summarized in
Table 1. Median patient age at time of treatment was 68.9 (range
43.9–89.2 years old). 51 patients received up to 6 months of andro-
gen deprivation therapy (ADT) prior to and during treatment,
at the discretion of the urologist. The median PSA at diagnosis
was 5.3 ng/mL. Fifty-nine patients have died, none from prostate
cancer.
BIOCHEMICAL DISEASE-FREE SURVIVAL
With a median follow up of 72 months, the 7-year actuarial bDFS
rate was 93.7% for all patients (Figure 1). It was 95.9 and 89.3%
for low- and intermediate-risk patients, respectively (p= 0.015)
(Figure 2). At last follow up, 59 patients had died, none from
prostate cancer, with 7-year actuarial survival of 85%.
There were 123 patients possessing a minimum of 7 years fol-
low up (range 84–96 months). For the first 50 patients treated, all
of whom received 35 Gy, the 8-year bRFS is 97.9% with a median
follow up of 96 months. Of this group, 41 patients had low-risk
disease.
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Table 1 | Patient characteristics at diagnosis.
Age at diagnosis Number of Patients Percent
Mean (range) 68.2
Median 68.6 (43.8–89.2)
40–49 4 0.8
50–59 72 15.1
60–69 190 39.8
70–79 180 37.7
80–89 31 6.5
PSA level at treatment (ng/mL)
Combined mean (range) 6
Median 5.3 (0.1–19)
PSA level at diagnosis Number of patients Percent p-Value
<4 ng/mL 79 16.6 0.08
4–10 ng/mL 353 74.0
>10–20 ng/mL 45 9.4
Risk Category
Low 324 67.9 0.015
Intermediate 153 32.1
Clinical Stage
T1a 2 0.4 <0.001
T1c 434 91
T2a 41 8.6
Gleason Score
6 354 74.2 0.008
7 (3+4) 83 17.4
7 (4+3) 40 8.4
HormoneTreatment
No 426 89.3 0.31
Yes 51 10.7
RTTreatment
35 Gy 154 32.3 0.098
36.25 Gy 323 67.7
Most of the failures were distant, as local failure defined by
positive biopsy was seen in only 0.9 and 2.6% of low- and
intermediate-risk patients, respectively.
Among patients with intermediate-risk disease, those consid-
ered to have low intermediate-risk (Gleason 6 with PSA >10,
or Gleason 3+ 4 with PSA <10; n= 106) had a significantly
higher bDFS than patients with high intermediate-risk (Gleason
3+ 4 with PSA 10–20 or Gleason 4+ 3; n= 47) (Figure 3). Low
intermediate-risk patients had a bDFS of 93.5 vs. 79.3% for high
intermediate-risk patients (p= 0.0036).
On univariate analysis, the addition of ADT was not a sig-
nificant predictor of bDFS (Table 1). T-stage (p< 0.001) and
Gleason score (p= 0.008) were significant predictors of outcome
(Figures 4 and 5). Low-risk and low intermediate-risk group
patients were stratified by dose (35 vs. 36.25 Gy, Figure 6), and
dose was not significant for bDFS (p= 0.36), with 7y bDFS of
97.7 and 94.5%, respectively. There was no statistically significant
difference between patients with Gleason score 3+ 3= 6 and
FIGURE 1 | Biochemimical disease-free survival in entire patient cohort.
FIGURE 2 | Biochemical disease-free survival stratified by D’Amico risk
group.
3+ 4= 7, though p-value trended toward significance (p= 0.058)
(Figure 7).
MULTIVARIATE ANALYSIS
Results of Cox multivariable regression analysis are shown in
Table 2. Pretreatment risk factors analyzed included baseline
PSA (above and below 10 ng/mL), clinical T-stage, use of ADT,
age (above and below median), and Gleason score (3+ 3, 3+ 4,
vs. 4+ 3). Variables found to be significant predictors for bio-
chemical failure were T-stage (p= 0.0045, RR of 4.34) and PSA
(p= 0.043, RR 3.21). Gleason score trended toward significance,
with p= 0.073, RR 2.79.
PSA TREND
PSA decline after SBRT gradually fell to an overall median of
0.11 ng/mL at 7 years (Figure 8). For the cohort of patients with 8-
year follow up, median PSA remained low, at 0.11 ng/mL. Median
time to nadir was 48 months (range, 3–84 months). A PSA bounce
of >0.2 ng/mL was noted among 16% of patients at a median
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FIGURE 3 | Biochemical disease-free survival in intermediate-risk
group patients. Patients were stratified into low intermediate-risk and high
intermediate-risk based on Gleason score and PSA. Patients deemed to be
intermediate-risk due to one factor alone, of either Gleason score 3+4 or
PSA 10–20, were considered to be intermediate-risk. Patients with Gleason
4+ 3 or 3+4 with PSA 10–20, were considered to be high
intermediate-risk.
FIGURE 4 | Biochemical disease-free survival stratified byT-stage.
of 36 months (range, 3–60 months), with median bounce height
of 0.50 ng/mL (range, 0.2–5.29). There was no statistically sig-
nificant difference in bDFS for patients with PSA bounce vs. no
bounce. Dose made no difference in the level of median PSAs at
all measurement points (Figure 9).
TOXICITY
There was no grade 3–4 acute GI or GU toxicity observed. Late
grade 3 GU toxicity (either retention requiring surgery or bleeding
requiring laser coagulation) occurred in nine patients (1.7%). All
grade 3 toxicity events occurred in the patient cohort that received
36.25 Gy. There was no late Grade 3–4 GI toxicity noted.
DISCUSSION
With the longest follow up of any published series using SBRT
for prostate cancer thus far, there remains a very high rate of
disease control in both low- and intermediate-risk patients. For
FIGURE 5 | Biochemical disease-free survival stratified by Gleason
score.
FIGURE 6 | Biochemical disease-free survival stratified by SBRT dose in
low-risk and low intermediate-risk group patients.
both risk groups, results are similar to other hypofractionated dose
schemes, such as HDR brachytherapy (16, 17). Compared to HDR
brachytherapy, SBRT is non-invasive and can be performed as an
outpatient procedure. SBRT may possibly have an advantage over
IMRT as well. Zelefsky et al. published a series on IMRT with sim-
ilar length of follow up (18). With 8-year median follow up, only
89 and 78% of low- and intermediate-risk patients were biochem-
ically controlled, respectively, which is inferior to our results for
SBRT. These results were corroborated by a series from Cleveland
Clinic, demonstrating 85 and 70% local control with 81 Gy IMRT
for low- and intermediate-risk patients, respectively (19). Radio-
biology suggests SBRT may deliver a higher BED to the prostate,
which may explain the discrepancy in local control between IMRT
and SBRT. For example, 35 Gy in five fractions has an EQD of
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FIGURE 7 | Biochemical disease-free survival comparing patients with
Gleason score 3+ 3 vs. Gleason score of 3+4.
Table 2 | Relative risk and p-value from Cox regression multivariable
analysis for pretreatment predictors of biochemical failure.
p-Value RR 95% CI
Age (median 68.6) 0.44 1.38 0.60 3.26
T-stage (T1 vs. T2) 0.0045 4.34 1.64 10.35
PSA 0.043 3.21 1.039 8.27
Hormones (N vs. Y) 0.10 0.24 0.013 1.26
Gleason score (≤3+4 vs. 4+3) 0.073 2.79 0.89 7.23
Categorical variables were age,T-stage, PSA (≥10 ng/mL), use of hormones, and
Gleason score.
90 Gy at 1.8 Gray fractions, using α/β ratio of 1.5. This higher
EQD may explain why the bDFS rates for SBRT and HDR seem
higher than IMRT with standard fractionation. Of course, mature
data from randomized control trials are required to confirm this
hypothesis.
After several years of follow up, PSA values drop to very low lev-
els. As we see in our study, the median PSA is 0.4 ng/mL at 2 years
and 0.2 ng/mL at 4 years. There are data suggesting that low PSA
values predict durability of response (20). Consistent with this, our
high biochemical control rates in short-term follow up translate to
consistently high rates of biochemical control at long-term follow
up of as long as 8 years. We predict there will be a continuation of
biochemical disease control as patients are followed out beyond
10 years, as our present median PSA values remain quite low, at
0.1 ng/mL.
Our results continue to suggest that, even at longer follow up,
there is no benefit in using higher dose SBRT. There is no sig-
nificant difference in bDFS or median PSA. This finding can help
guide SBRT dose selection, as 35 Gy appears to be just as effective as
higher dose SBRT, at least for low- and intermediate-risk patients.
We predict that increasing the SBRT dose above 35 Gy will result
FIGURE 8 | Median PSA value in the entire patient cohort. Error bars
reflect interquartile range. The Number of patients with PSA data at each
time point is listed below. Patients with biochemical recurrence are
excluded.
FIGURE 9 | Median PSA value stratified by dose. There was no
significant difference between median PSA values for any of the data
points. The Number of patients with PSA data at each time point is listed
below. Patients with biochemical recurrence are excluded.
in increased toxicity without yielding improvement in outcomes;
there are now reports suggesting this to be the case (21, 22). We
hypothesize that this is due to a sigmoid dose–response curve for
prostate cancer. There is a study from Jefferson University that
analyzed over 10,000 patients using a variety of dose regimens,
and demonstrated that a BED of 200 Gy maximized local control
for prostate cancer, across all risk groups, because this was the
beginning of the flattening of the dose–response curve (23). SBRT
to 35 Gy is equivalent to 90 Gy at 1.8 Gy/fraction, or 200 BED (α/β
of 1.5). Assuming these findings are true, then increasing SBRT
dose above 35 Gy (and thus above BED of 200) will not provide
any local control advantage.
Looking at the intermediate-risk group, a few observations of
importance can be made. First, our results are comparable to
reports on use of HDR brachytherapy as a boost after external
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beam therapy (16, 17). Thus, SBRT alone (without EBRT), may
possibly be an excellent treatment for intermediate-risk disease.
We have previously published data suggesting that, for high-
risk disease, there is no benefit in performing EBRT+ SBRT,
compared to SBRT alone (24). Secondly, SBRT yields different
biochemical disease control rates for the high intermediate-risk
patients than for the low intermediate-risk patients. In fact, the
low intermediate-risk group has a control rate that is similar to
low-risk patients. We hypothesize that the decreased bDFS in the
high intermediate-risk group is secondary to a greater propensity
to develop distant metastatic disease, rather than a greater like-
lihood of local failure. If so, increasing the radiation dose to the
prostate would not be expected to improve biochemical DFS. Our
data also show no significant benefit for use of of ADT. As with
high-risk patients, strategies such as use of adjuvant chemother-
apy should be explored to try to reduce the risk of distant disease
progression.
CONCLUSION
CyberKnife SBRT produces excellent long-term biochemical con-
trol rates. Median PSA levels continue to compare favorably with
other radiation modalities and with long-term follow up, results
continue to demonstrate durability of response. It appears that
35 Gy is as effective as 36.25 Gy for low-risk and low intermediate-
risk patients. Randomized trials will be necessary to prove whether
there is an advantage over standard dose IMRT.
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